PPARA and renal cell carcinoma: The PPARα antagonist GW6471 attenuated enhanced fatty-acid oxidation and oxidative phosphorylation, blocked enhanced glycolysis, and reduced tumor growth in a renal-cell carcinoma model in nude mice [194].